TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03249571

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Flavonoid supplement
Description: 2-weeks ingestion of flavonoid supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2-week ingestion of placebo supplement
Study: NCT03178227

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Photoaging Mirroring Intervention
Description: Medical students perform mirroring with the pupils in the schools where they shoot selfies with tablets and photoage them to future non-smokers vs. future smokers.
Study: NCT00121212

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: carbon-11 acetate PET scan

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: carbon-11 acetate PET scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: carbon-11 acetate PET scan
Study: NCT01384578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pentoxiphylline and Vitamin E
Description: Patients in cases group (Group 1) will receive pentoxiphylline (PTX) 400 mg thrice daily and vitamin E 800 IU/day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin E
Description: Patients in control group will receive vitamin E 800 IU/day
Study: NCT01612260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shensong Yangxin capsule
Description: ShenSongYangXin Capsule 4 granules t.i.d. po for 12weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo Capsule
Description: 4 granules t.i.d. po for 12 weeks
Study: NCT01052311

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tredaptive (1 g extended release niacin+ 20 mg laropiprant)
Description: Laropiprant (LRP; Merck \& Co., Inc, Whitehouse Station, NJ, USA) is a potent, once-daily, highly selective PGD2-receptor (DP1) antagonist. A combination tablet containing 1 g of extended-release niacin and 20 mg of laropiprant (ERN/LRPT) once daily for the first 30 days. from day 31 to 90 it will be 2 g of extended-release niacin and 20 mg laropiprant once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tredaptive
Description: Tredaptive 1 g \[Laropiprant 20 mg(LRP; Merck \& Co., Inc, Whitehouse Station, NJ, USA) and 1 g of extended-release niacin\]from day 1 to 30 once daily. From day 31 to 90, the same but 2 g instead of 1 g of extended-release niacin.
Study: NCT02826109

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PeriAcryl®90 HV
Study: NCT04505228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Safflower (Carthamus Tinctorius) IgG4 &#X7C; Serum &#X7C; Allergy
Description: The designed Chinese herb formulas

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine Sulfate
Description: The basic treatment for heart disease

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine Sulfate
Description: The basic treatment for heart disease
Study: NCT00388908

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminders and opinion leader generated guidelines +/- leaflets and counselling

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Study: NCT03064477

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unified Protocol
Description: Intervention group that carries out the Unified Protocol in a group format

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy (TAU)
Description: TAU group that carries out Cognitive Behavioral Therapy in an individual format
Study: NCT01112046

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic submucosal dissection
Description: Endoscopic treatment (performed under conscious sedation) using specific endoscopic knives

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic resection
Description: Surgical treatment performed under general anesthesia
Study: NCT02150590

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: Nocturnal nasal oxygen during stay at 2048 m

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxygen
Description: Nocturnal nasal oxygen during stay at 2048 m

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sham oxygen (room air)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sham oxygen (room air)
Study: NCT03875144

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PIPAC
Description: Pressurized IntraPeritoneal Aerosol Chemotherapy of Cisplatin 10.5mg/m² + Doxorubicin 2.1 mg/m² every 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: standard intravenous chemotherapy for mesothelioma (Cisplatin 75mg/m² + Pemetrexed 500mg/m²)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: standard intravenous chemotherapy for mesothelioma (Cisplatin 75mg/m² + Pemetrexed 500mg/m²)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: standard intravenous chemotherapy for mesothelioma (Cisplatin 75mg/m² + Pemetrexed 500mg/m²)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: standard intravenous chemotherapy for mesothelioma (Cisplatin 75mg/m² + Pemetrexed 500mg/m²)
Study: NCT00881777

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency heating of the myocardial infarct scar
Description: Radiofrequency energy is applied to the epicardial surface of the heart using an external generator and a hand-held probe to heat myocardial infarction scar.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary Artery Bypass Grafting (CABG) surgery
Description: A standard surgical procedure performed to relieve angina and reduce the risk of death from coronary artery disease. Arteries or veins from elsewhere in the body are grafted to the coronary arteries to bypass atherosclerotic narrowings and improve the blood supply to the coronary circulation supplying the myocardium.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary Artery Bypass Grafting (CABG) surgery
Description: A standard surgical procedure performed to relieve angina and reduce the risk of death from coronary artery disease. Arteries or veins from elsewhere in the body are grafted to the coronary arteries to bypass atherosclerotic narrowings and improve the blood supply to the coronary circulation supplying the myocardium.
Study: NCT03643874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Halix albuterol 90 mcg
Description: albuterol unit dose disposable DPI delivers 90 mcg of albuterol in the excipient lactose with each inhalation. Albuterol 90 mcg will be given on one of the treatment days in cumulative doses up to a total dose of 720 mcg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: albuterol HFA MDI 90 mcg
Description: albuterol HFA MDI delivers 90 mcg of albuterol with each inhalation. Albuterol 90 mcg will be given on one of the treatment days in cumulative doses up to a total dose of 1440 mcg
Study: NCT02911532

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tissue engineering conjunctiva transplantation
Description: During the operation,transplant the tissue engineering conjunctiva to the conjunctiva loss position
Study: NCT03444285

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Warm Up
Description: Run on a treadmill during 10 minutes without fatigue of the participant after this time.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hot Pack
Description: 20 minutes of hot-pack on both hamstring
Study: NCT03721094

Intervention type: OTHER
Group type: OTHER
Intervention: Immersive virtual reality
Description: In the IVR environment, four different 360-degrees videos were in sequence played as backdrop during the procedure. The videos reflected real life situations in the operating room with two videos representing calm periods, one video representing a light stressor and one video representing a severe stressor with a bleeding (2 ml/s) being triggered in the simulation. Participants complete the procedures while wearing the head mounted device.
Study: NCT02863809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riboflavin
Description: Riboflavin, a water soluble vitamin, is an essential nutrient and a natural component of many foods.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riboflavin
Description: Riboflavin, a water soluble vitamin, is an essential nutrient and a natural component of many foods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextran
Description: Dextran is used to increase the viscosity of the solution.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextran
Description: Dextran is used to increase the viscosity of the solution.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UVA Light Source
Description: Avedro's KXL® System is a UVA irradiation system that uses a light emitting diode (LED) to deliver a dose of UVA light to a targeted treatment area for illuminating the cornea during corneal collagen cross-linking.
Study: NCT02555670

Intervention type: OTHER
Intervention: BIA
Description: Bioelectrical impedance analysis was performed within 4 days after a CT-scan was made
Study: NCT02876887

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cocoa

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03350217

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eleview
Description: If a lesion in the colon is found to fit the description listed in the protocol, the subject will be randomized to Eleview or Hetastarch as the injectate solution for the procedure. The injectate solution is used, as needed, to aid in the resection of the target lesion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hetastarch
Description: If a lesion in the colon is found to fit the description listed in the protocol, the subject will be randomized to Eleview or Hetastarch as the injectate solution for the procedure. The injectate solution is used, as needed, to aid in the resection of the target lesion.
Study: NCT03070158

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attachment Promotion
Description: Attachment Promotion consists of:~1. Education session about newborn and mother care.~2. Training in multisensory stimulation using the ATVV Intervention (auditory, tactile, visual and vestibular)~3. Two domiciliary visits to follow up and to give education about newborn care and ATVV Intervention.~4. Daily Phone follows up.
Study: NCT03053479

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic sacrocolpopexy
Description: see arm/group descriptions

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transvaginal mesh procedure
Description: see arm/group descriptions

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Amreich-Richter procedure
Description: see arm/group descriptions
Study: NCT02918019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSTT1041A
Description: MSTT1041A will be administered as subcutaneous injections.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSTT1041A
Description: MSTT1041A will be administered as subcutaneous injections.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSTT1041A
Description: MSTT1041A will be administered as subcutaneous injections.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched with MSTT1041A.
Study: NCT00584480

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric Oxygen Treatment (HBOT)
Description: 1.5 ATA at 100% Oxygen of HBOT
Study: NCT01704352

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral therapy for insomnia
Description: CBT-I will be given during 3-6 sessions according to need by two therapists being either psychiatrists or psychologists with clinical experience in CBT-I.
Study: NCT03353870

Intervention type: OTHER
Intervention: qualitative interview
Description: individual qualitative interview
Study: NCT01019382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipidem fish oil infusion + Gemcitabine chemotherapy
Description: 500mls intravenous infusion once a week of lipidem in addition to standard starting dose of gemcitabine (1000mg/m2) Dose can be reduced if poorly tolerated
Study: NCT03099486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: The dose of Regorafenib is 160 mg PO daily D1-D21 of 28-day cycle or last tolerated dose while on Regorafenib monotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 5-FU dose D1 and D15 of 28 day cycle i400 mg/m2 bolus over 10 mins followed by 2400 mg/m2 continuous infusion over 46 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: D1 and D15 of 28 day cycle Leucovorin 400 mg/m2 over 2 hours,
Study: NCT04312490

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: endomyocardial biopsy
Description: Endomyocardial biopsies will be stained with Masson's trichrome as well as Giemsa and examined by light microscopy. For immunohistology, tissue sections will be treated with an avidin-biotinimmunoperoxidase method (Vectastain-Elite ABC Kit, Vector, Burlingame, Calif), with application of the following monoclonal antibodies: CD3 (T cells; Novocastra Laboratories, Newcastle, UK), CD68 (macrophages, natural killer cells; DAKO, Hamburg, Germany), and HLA-DR-α (DAKO, Hamburg, Germany
Study: NCT02481388

Intervention type: OTHER
Intervention: Maximal exercise ramp test
Description: The maximal exercise ramp test, symptom-limited, performed by all patients in the study was performed based on treadmill ramp protocol through ErgoPC Elite® software associated with 12-channels electrocardiogram. Respiratory variables were obtained in standard conditions of temperature, pressure and humidity (StPD), breath-by-breath, with the patient breathing through a face mask without leaks coupled to gas analyzer (Cortex - Metamax 3B, Germany).To ensure that patients reached maximum effort during the examination, only the tests which patients obtain a respiratory exchange ratio (RR) ≥1.1 were accepted .

Intervention type: OTHER
Intervention: Maximal exercise ramp test
Description: The maximal exercise ramp test, symptom-limited, performed by all patients in the study was performed based on treadmill ramp protocol through ErgoPC Elite® software associated with 12-channels electrocardiogram. Respiratory variables were obtained in standard conditions of temperature, pressure and humidity (StPD), breath-by-breath, with the patient breathing through a face mask without leaks coupled to gas analyzer (Cortex - Metamax 3B, Germany).To ensure that patients reached maximum effort during the examination, only the tests which patients obtain a respiratory exchange ratio (RR) ≥1.1 were accepted .
Study: NCT00411554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin phosphate
Description: sitagliptin 50 mg orally once daily QD. Duration of Treatment: 12 Weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: voglibose
Description: voglibose 0.2 mg orally three times daily TID. Duration of Treatment: 12 Weeks
Study: NCT03216356

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT + ImRs
Description: Cognitive Behavioral Therapy with Imagery Rescripting

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT + ImRs
Description: Cognitive Behavioral Therapy with Imagery Rescripting

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT + I.E.
Description: Cognitive Behavioral Therapy with Imagery Exposure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-Cycloserine
Description: 250 mg DCS (derived from Seromycin 250 mg capsules)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: polyethylene glycol 3350 powder

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Study Pill
Description: 250 mg DCS (derived from Seromycin 250 mg capsules) or polyethylene glycol 3350 powder
Study: NCT03355508

Intervention type: DEVICE
Group type: OTHER
Intervention: pucture in the arteriovenous fistula
Description: The compression time will be measured with a stopwatch so that it is objective and accurate, although the compression times range from minute to minute.~An initial 2-week observation phase (phase 1) will establish a reference time for each patient using the most common puncture technique in the department: bevel up.~We will evaluate the patient's reference time by counting the time of compression using a stopwatch for 2 weeks (ie 6 sessions) and we will take an average.~A draw will determine for each patient the order in which the direction of the needles will be used.~After this determination of the reference time, the patient will enter two successive phases where it will be punctured bevel up (phase 2) and then down (phase 3) or vice versa following the draw.

Intervention type: DEVICE
Group type: OTHER
Intervention: pucture in the arteriovenous fistula
Description: The compression time will be measured with a stopwatch so that it is objective and accurate, although the compression times range from minute to minute.~An initial 2-week observation phase (phase 1) will establish a reference time for each patient using the most common puncture technique in the department: bevel up.~We will evaluate the patient's reference time by counting the time of compression using a stopwatch for 2 weeks (ie 6 sessions) and we will take an average.~A draw will determine for each patient the order in which the direction of the needles will be used.~After this determination of the reference time, the patient will enter two successive phases where it will be punctured bevel up (phase 2) and then down (phase 3) or vice versa following the draw.
Study: NCT02870361

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intranasal insulin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03090594

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Biopsy
Description: Is to obtain pulmonary parenchyma samples using a flexible bronchoscope.
Study: NCT01891331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VT-1161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VT-1161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VT-1161

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluconazole
Study: NCT03624322

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zyprexa IM
Description: 5mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zydis
Description: 10mg orally disintegrating wafer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INP105
Description: Single, ascending doses of 5, 10, or 20mg capsules OLZ (olanzapine) or placebo (MCC)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: I231 POD® Device
Description: Precision Olfactory Delivery (POD) device
Study: NCT02171585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Study: NCT01081795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: In the titration period, topiramate 25-mg tablet once daily orally for 1 week, the dose will be increased by 1 tablet every week up to twice daily for a total of 4 weeks so that the total daily dose given is 50 mg or 100mg. The dose given in the final titration week will be continued for further 18 weeks (fixed dose period).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: In the titration period, topiramate 25-mg tablet once daily orally for 1 week, the dose will be increased by 1 tablet every week up to twice daily for a total of 4 weeks so that the total daily dose given is 50 mg or 100mg. The dose given in the final titration week will be continued for further 18 weeks (fixed dose period).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In the titration period, matching placebo tablet once daily orally for 1 week, the dose will be increased by 1 tablet every week up to twice daily for a total of 4 weeks. The dose given in the final titration week will be continued for further 18 weeks (fixed dose period).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: In the titration period, matching placebo tablet once daily orally for 1 week, the dose will be increased by 1 tablet every week up to twice daily for a total of 4 weeks. The dose given in the final titration week will be continued for further 18 weeks (fixed dose period).
Study: NCT04758585

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopy
Description: Shoulder Arthroscopy
Study: NCT03534427

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Jump rope exercise intervention
Description: 12-week jump rope exercise program
Study: NCT00505999

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaire taking 30-40 minutes to complete.
Study: NCT03578120

Intervention type: BIOLOGICAL
Intervention: Pre-school booster vaccine
Description: Routine vaccination with pre-school booster vaccine

Intervention type: BIOLOGICAL
Intervention: Pre-school booster vaccine
Description: Routine vaccination with pre-school booster vaccine

Intervention type: BIOLOGICAL
Intervention: Pre-school booster vaccine
Description: Routine vaccination with pre-school booster vaccine
Study: NCT05823597

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sugar Intensive Treatment
Description: see arm description

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General Health Control
Description: see arm description
Study: NCT01365559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group A: Carfilzomib & Non-IMiD Regimen
Description: Carfilzomib will be administered intravenously starting at a dose of 20 mg/m\^2 over 30 minutes for the first cycle and will then be increased to 27, 36 and 45 mg/m2 during cycles 2-4, respectively. Doses will be administered IV once daily on days 1, 2, 8, 9, 15, and 16 of each cycle. Cycles will be 28 days in length.~Combination non-IMiD drug is dosed on the identical schedule and dosage as patient was in previous bortezomib containing regimen.~Maintenance regimen maybe administered if patient does not progress while on study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group B: Carfilzomib & IMiD containing regimen.
Description: Carfilzomib will be administered intravenously starting at a dose of 20 mg/m\^2 over 30 minutes for the first cycle and will then be increased to 27, 36 and 45 mg/m2 during cycles 2-4, respectively. Doses will be administered IV once daily on days 1, 2, 8, 9, 15, and 16 of each cycle. Cycles will be 28 days in length.~Combination IMiD drug is dosed on the identical schedule and dosage as patient was in previous bortezomib containing regimen.~Maintenance regimen maybe administered if patient does not progress while on study.